PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

Merz Pharma invests with venture capital for innovations in the aesthetics market

Merz Pharma is planning to invest up to EUR25 million corporate venture capital in the Aesthetics market.  Funding will be focused on early-stage start-up companies as well as research projects, specifically in the areas of anti-aging, skin rejuvenation and body-shaping. 

These specific investments complement Merz’s own research and development in which the company has recently invested close to 15 percent of its fiscal year 2013/14 EUR994 million sales revenue. Merz has significantly expanded within the Aesthetics sector in recent years through the acquisitions of Ulthera, Neocutis, Anteis and BioForm Medical and is aiming for further enhancements in this attractive market segment. 

“The global Aesthetics market is showing dynamic development and provides a highly promising environment for differentiating concepts and innovative technologies,” says Hans-Jörg Bergler, member of the executive board and responsible for Corporate Development. He adds: “With our investments we want to primarily foster early-stage Aesthetic concepts that will be launched within five to ten years, providing clear benefits for physicians and patients.” 

The aim of the investment is to help foster innovative companies – for example in the US, Europe and Israel – in the early stages of product development and, if the development is successful, to become a long-term investor and partner. Additionally, Merz is open to provide support for the companies through its expertise within the Aesthetics field, its research experience and its international presence. The company has research centres in Europe and the US, as well as a global network that includes 22 subsidiaries, its products are sold in over 100 countries around the world.

The allocation of venture capital is part of the long-term innovation and growth strategy of Merz within the Aesthetics field. Through the takeover of Neocutis, Anteis and BioForm Medical, Merz has significantly expanded its Aesthetics business in recent years. The acquisition of Ulthera and its innovative ultrasound-technology have strengthened Merz’ power of innovation. 

“We have a strong platform in the Aesthetics field and want to make sustainable investments in our innovation and development”, says Bergler. “Furthermore, with the venture capital we want to foster new innovative products and technologies, as there is still a need for new concepts in aesthetic dermatology, for example in the areas of cellulitis, loss of hair and age marks.”

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured